RecruitingNot ApplicableNCT06598839

Immuno-effect of Tα1 for Stage I NSCLC

Assessment of the Efficacy of Immunomodulatory Therapy With Thymosin Alpha 1 (Tα1) Following Surgical Resection in Patients With Stage I Non-Small Cell Lung Cancer

Sponsor

Yousheng Mao

Enrollment

40 participants

Start Date

Jun 30, 2024

Study Type

INTERVENTIONAL

Conditions

Non-small Cell Lung Cancer

Summary

To explore the effect of thymosin alpha 1 (Tα1) on postoperative peripheral blood circulating tumor cells and immunosenescence in patients with early-stage non-small cell lung cancer (NSCLC).

Eligibility

Min Age: 18 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This study is testing whether a drug called Thymosin alpha-1 (Tα1) — an immune-boosting agent — can improve immune function and outcomes in patients with early-stage (Stage I) non-small cell lung cancer after surgical removal. **You may be eligible if...** - You have been confirmed with Stage I non-small cell lung cancer - Your tumor can be removed surgically - You are scheduled for lobectomy (removal of a lung lobe) with lymph node removal - You are between 18 and 75 years old - You have good heart, lung, liver, and kidney function for surgery - You have not previously received any cancer treatment **You may NOT be eligible if...** - Your lung cancer is confirmed as non-invasive, small cell, or a benign lesion - You have a known or suspected autoimmune disease - You are allergic to thymopeptides - You have had blood clots, stroke, or other serious vascular events in the past 6 months - You have active severe infections or other serious uncontrolled illnesses Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGThymosin Alpha1

subcutaneous injection of Tα1, 1.6mg each time, biw, for 3 months

Locations(1)

National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College

Beijing, Beijing Municipality, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06598839

Related Trials

Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations

NCT06357533283 locations

Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)

NCT066944541 location

Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan

NCT0500540346 locations

CHOICE:Decision Factor of EGFR-TKI in Chinese IV NSCLC

NCT074137571 location

Prospective External Control Cohort In Patients With Newly Diagnosed Advanced or Metastatic EGFR Mutant Non-Small Cell Lung Cancer

NCT070284898 locations